Form 8-K - Current report:
SEC Accession No. 0000950170-23-041327
Filing Date
2023-08-10
Accepted
2023-08-10 16:11:15
Documents
15
Period of Report
2023-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K onct-20230810.htm   iXBRL 8-K 67475
2 EX-99.1 onct-ex99_1.htm EX-99.1 148722
3 GRAPHIC img119983317_0.jpg GRAPHIC 7250
  Complete submission text file 0000950170-23-041327.txt   380758

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT onct-20230810.xsd EX-101.SCH 2902
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT onct-20230810_pre.xml EX-101.PRE 13506
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT onct-20230810_def.xml EX-101.DEF 13484
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT onct-20230810_lab.xml EX-101.LAB 16665
9 EXTRACTED XBRL INSTANCE DOCUMENT onct-20230810_htm.xml XML 4715
Mailing Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

EIN.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 231159476
SIC: 2834 Pharmaceutical Preparations